EBV activates the Nrf2/Keap1–SLC7A11/GPX4 axis, enhancing antioxidant defenses and suppressing ferroptosis, which contributes to both tumor progression and therapy resistance [25,60]. The gene discussed is SLC7A11; the disease is neoplasm.